For research use only. Not for therapeutic Use.
BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects[1].
BPR1M97 (1.8 mg/kg; s.c.; once) demonstrates antinociception in a murine model of cancer pain[1].
| Catalog Number | I017818 |
| CAS Number | 2059904-66-2 |
| Synonyms | 3,4-dichloro-N-[(2-methyl-3,4-dihydro-1H-isoquinolin-1-yl)methyl]benzamide |
| Molecular Formula | C18H18Cl2N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C18H18Cl2N2O/c1-22-9-8-12-4-2-3-5-14(12)17(22)11-21-18(23)13-6-7-15(19)16(20)10-13/h2-7,10,17H,8-9,11H2,1H3,(H,21,23) |
| InChIKey | LIYLICKKTYEDQP-UHFFFAOYSA-N |
| SMILES | CN1CCC2=CC=CC=C2C1CNC(=O)C3=CC(=C(C=C3)Cl)Cl |
| Reference | [1]. Chao PK, et al. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, producespotent antinociceptive effects with safer properties than morphine. Neuropharmacology. 2019 Jul 3:107678. |
